VOR Stock — Vor Biopharma Inc.

Vor Biopharma Inc. (VOR)

Updated October 16, 2026.

VOR is a Stock. Total return is -97.6% over the past 5.7 years, 210.1 points behind SPY at 112.5%.

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company developing telitacicept, a novel fusion protein candidate for treating autoimmune diseases including generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's disease, and IgA nephropathy, with rights to the therapy obtained through a license agreement with RemeGen Co., Ltd. The company does not currently distribute to shareholders. Vor Biopharma appeals to investors seeking exposure to early-stage drug development in the autoimmune disease space, though as a pre-revenue clinical-stage company it carries substantial development and regulatory risk.

VOR performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.6% over the past 5.7 years, 210.1 points behind SPY at 112.5%. Over the past year its total return — price change plus distributions reinvested — is -38.0%. Its deepest 1-year drawdown was 76.7%.

VOR key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2021

Distribution frequency

None

Last close

$18.03 (as of 2026-10-16)

Market cap

$976,971,362

Average volume

733077.0

Beta

1.783

Payout ratio

0.0%

P/E ratio

0.1

EPS

$181.14

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VOR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 76.7%.

Who may consider VOR — and who may not

It is a weaker fit for investors who need monthly cash flow (VOR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VOR

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions